OPEN

A Web-based Prediction Model for Early Death in Patients With Metastatic Triple-negative Breast Cancer

Wen-kai Pan, MMed, Si-yan Ren, MMed,† Liao-xiang Zhu, MMed,* and Bao-chai Lin, MMed**

Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2. This subtype of breast cancer is known for its high aggressiveness, high metastatic potential, tendency for recurrence, and poor prognosis. Patients with metastatic TNBC (mTNBC) have a poorer prognosis and a higher likelihood of early death (survival time ≤ 3 months). Therefore, the development of effective individualized survival prediction tools, such as prediction nomograms and web-based survival calculators, is of great importance for predicting the probability of early death in patients with metastatic TNBC.

Methods: Patients diagnosed with mTNBC in the Surveillance, Epidemiology, and End Results database between 2010 and 2015 were included in the model construction. Univariate and multivariate logistic regression analysis was performed to identify risk factors associated with early death in patients with mTNBC and predictive prognostic nomograms were constructed. The accuracy of the nomograms was verified using receiver operating characteristic curves, and GiViTi Calibration belt plots were used to evaluate the model consistency. The clinical applicability of the nomograms was evaluated using decision curve analysis. On the basis of the predictive prognostic nomograms, a network survival rate calculator was developed for individualized survival prediction in patients with mTNBC.

Results: A total of 2230 patients diagnosed with mTNBC were included in the Surveillance, Epidemiology, and End Results database for this study. After strict exclusion criteria, 1428 patients were found to be eligible for the study. All the patients were randomly divided into a training cohort and a validation cohort in a ratio of 7:3. Independent risk factors for mTNBC, including age, tumor size, brain metastasis, liver metastasis, surgery, and chemotherapy, were identified and integrated to construct the prediction nomogram and survival calculator. Results of receiver operating characteristic curves, calibration curves, and decision curve analysis curves from the training and validation cohort confirmed that the developed nomogram and web-based survival calculator in this study could accurately predict the probability of early death in patients with mTNBC.

Conclusions: In this study, we developed a reliable prediction nomogram and web-based survival calculator for predicting the probability of early death in patients with mTNBC. These tools can assist clinical physicians in identifying high-risk patients and developing personalized treatment plans as early as possible.

Key Words: triple-negative breast cancer (TNBC), nomogram, predictive model, early death

(*Am J Clin Oncol* 2024;47:71–80)

Breast cancer is the most prevalent malignancy among women, with breast cancer–specific deaths accounting for ~15% of cancer-related deaths in 2018.[1] Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2.[2] Epidemiological data indicate that TNBC primarily affects young premenopausal women under the age of 40, representing ~10% to 20% of all breast cancer cases.[3,4] This subtype of breast cancer is known for its aggressive biology, early onset of metastatic disease, visceral metastases, rapid disease progression, short response time to available therapies, and poor survival outcomes.[5] Chemotherapy is the primary treatment for patients with TNBC.[6]

Because of the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, TNBC is highly aggressive and has a worse prognosis than other subtypes of breast cancer, representing a mortality rate of 40% within the first 5 years of diagnosis.[5] Furthermore, ~46% of patients with TNBC develop distant metastases[7] occurring within the third year of diagnosis.[8] These metastases commonly involve the brain and visceral organs. Forty percent of metastases are occurred in the lung, which is one of the most common sites of distant metastasis. The mortality rate of distant metastasis is higher than that of carcinoma in situ.[9] The median survival time after metastasis is only 13.3 months, and the postoperative recurrence rate is as high as 25%. The median survival time of patients with metastatic TNBC is 1 to 1.5 years,[10] and the mortality rate of these patients could gradually decrease with the advancement of treatments. However, the survival rate for these patients remains suboptimal.[11–15]

Currently, the American Joint Committee on Cancer (AJCC) TNM staging system is a widely accepted tool for predicting the survival of breast cancer patients. However, its predictive value is limited when applied to patients with metastatic disease. To date, there have been no comprehensive studies using predictive models to determine the incidence of early death in patients with metastatic triple-negative breast cancer (mTNBC). Therefore, it is crucial to identify a new method for predicting the probability of early death in mTNBC patients. There is an urgent need for a simple and accurate model for assessing these patients' risk of early death. Recent studies have shown that the nomogram is a convenient and accurate tool to assess the prognosis of cancer patients.[16,17]

From the *Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University; and †Medical and Radiation Oncology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.

L.B.C.: created design and main manuscript text P.W.K. and R.S.Y.: supplied the research subjects or participants and conducted the data analysis. P.W.K. and Z.L.X.: revised the manuscript.

The authors declare no conflicts of interest.

Correspondence: Bao-chai Lin, MMed, Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China. E-mail: linbaochai@wzhospital.cn.

ISSN: 0277-3732/24/4702-0071
DOI: 10.1097/COC.0000000000001058

Nomograms could combine important factors to quantify the probability of patients experiencing a certain clinical event, such as survival or recurrence rates. Therefore, nomograms have become a useful clinical tool for facilitating decision-making and risk stratification. However, there is a lack of studies on nomograms for predicting early death in patients with mTNBC,[16] and little is known about the risk factors for early death in this patient population.

In light of this, there is a need to construct a nomogram for predicting early death in patients with mTNBC to better assess the survival and prognosis of these patients. Since a manual calculation may limit the nomogram's usefulness in clinical practice, a network calculator based on prognostic nomograms can improve the accuracy and usability of disease survival prediction when compared with prognostic nomograms alone. This study explores the risk factors of early death in patients with mTNBC using the Surveillance, Epidemiology, and End Results (SEER) database and constructs a nomogram and a network survival calculator. These tools not only assist clinicians in identifying high-risk patients but also guide treatment decision-making and monitoring. Furthermore, these tools can help formulating timely individualized treatment plans, ultimately extending life expectancy, improving patients' quality of life, and reducing the economic burden on society and families.

METHODS

SEER database (https://seer.cancer.gov/) is the National Cancer Institute's publicly available database containing cancer incidence and survival data from 17 established cancer registries across the United States. The present authors obtained authorization from the National Cancer Institute (USA) to access research data on cancer patients (reference number: 17461-November 2020) from the SEER database. Using the data from the SEER database does not require informed consent from patients, as cancer is a reportable disease in every state of the United States. This study adheres to the ethical standards outlined in the 1964 Declaration of Helsinki and its subsequent amendments or similar ethical guidelines.

Patient Cohorts

Data of patients with mTNBC for this present study were extracted from the SEER*Stat (version 8.4.0.1) database during the period from 2010 to 2015. The inclusion criteria for the study were as follows: (1) patients were diagnosed with TNBC; (2) patients had demographic information, including age, marital status, and race; (3) patients had clinical and pathologic information, including primary tumor site, stage, histologic type, TNM, and tumor size. The exclusion criteria for the study were as follows: (1) patients with unknown survival time; (2) patients with unknown race; (3) patients with no identified primary tumor or unknown tumor site, size, degree of infiltration, stage, or lymph node metastasis; (4) patients with unknown marital status; (5) patients under 18 years of age.

Data Collection

Figure 1 illustrates the screening process of patients in this study. Taking into account the aggressive nature of mTNBC and previous research, early death was defined as death within 3 months of initial diagnosis. All-cause early death was defined as death from any cause (such as hypertension, diabetes mellitus, coronary artery disease, traffic accidents, etc.) within 3 months of the patient's initial diagnosis with mTNBC.[18,19]



FIGURE 1. Flowchart for selection procedure of patients with mTNBC. mTNBC indicates metastatic triple-negative breast cancer; SEER, Surveillance, Epidemiology, and End Results; TNBC, triple-negative breast cancer.

Survival time was calculated from the date of the first histologic or cytologic diagnosis with mTNBC.

Finally, the study included 1428 patients with mTNBC, among which 275 patients were died within 3 months of their initial diagnosis. Patients were randomly divided into a training cohort (accounting for 70%) and a validation cohort (accounting for 30%). The prediction model was constructed using patients from the training cohort and subsequently validated using the corresponding patients in the validation cohort.

The baseline characteristics of patients, including age, sex, race, marital status, and tumor characteristics such as tumor location, size, histologic grade, AJCC seventh TNM stage, and presence of bone, brain, liver, and lung metastasis, were collected for analysis. In addition, the information on the treatment received, including surgery, radiotherapy, and chemotherapy, was also collected for analysis. The patient's age was classified into 4 groups: 49 years or below, 50 to 59 years, 60 to 69 years, and 70 years or above. In contrast, the tumor size was reclassified as <50, 50 to 100, and >100 mm. Race was divided into White, Black, or others. Histologic type was grouped as 8500 (invasive ductal carcinoma, ICD-O-3, code 8500/3) or others. Treatments and metastasis sites were grouped as "yes" or "no/unknown." Laterality was grouped into left, right.

Statistical Analysis

Categorical data were described using numbers and percentages (N, %), and χ^2 tests were used to compare subgroups. Statistical analysis was conducted using SPSS 24.0 and R software (version 4.1.0; http://www.r-project.org/). *P*-value of <0.05 (2-tailed) was considered statistically significant. Patients with mTNBC were randomly divided into training and validation cohorts, and the distribution of variables was compared using either Pearson χ^2 test or Fisher exact test.

In the training cohort, univariate logistic analysis was used to identify risk factors associated with mTNBC. Variables with $P < 0.05$ in the univariate analysis were subsequently included in the multivariate logistic analysis using the "Forward LR" method in SPSS 24.0 to determine independent risk factors for early mortality in patients with mTNBC.[20] Furthermore, a prognostic nomogram was developed using the "replot" package based on these independent risk factors, and various methods were used to evaluate its performance in the training and validation cohorts. A concordance index (C-index) was generated to measure prediction accuracy and discriminatory ability, while receiver operating characteristic (ROC) curves were plotted, and the area under the time-dependent receiver operating characteristic curve (AUC) was calculated to validate prediction accuracy.[21,22] Typically, the C-index and AUC values range from 0 to 1. When both the C-index and AUC values are >0.7, it could be considered as reasonable estimates. Moreover, the higher values reveal the greater predictive power. GiViTi Calibration belts were also constructed to a confidence interval around the calibration curve. The red line is the perfect calibration line between the predicted probability and observed. The light and dark gray calibration bands represent the 80% and 95% confidence levels for this predictive model, respectively.[23] If the red line is included in the calibration band, the model fits well when the *P*-value >0.05. Decision curve analyses (DCAs) were performed to assess the clinical applicability and the benefit of the nomogram.[24] This study aimed to develop a prognostic nomogram and a web-based survival calculator that can dynamically predict the early mortality probability of mTNBC through a population-based retrospective cohort study using the SEER database data.

RESULTS

Baseline Characteristics of the Study Population

A total of 2230 patients diagnosed with mTNBC were included in the study from the SEER database. After applying the strict exclusion criteria, 1428 patients were found to meet the study requirements. As shown in Table 1, 19.3% (275/1428) of mTNBC patients died within 3 months of diagnosis. The majority of mTNBC patients were White (70.2%), and bone metastases were the most common type (41.1%) compared with liver (27.2%), brain (10.9%), and lung (39.8%) metastases. Most patients with mTNBC received chemotherapy (77.2%), while only a minority chose radiotherapy (35.1%). The probability of morbidity in the left breast (52.6%) was higher than that in the right breast (47.4%). The early mortality rate in whites (71.3%) was higher than that in other racial groups. Treatments, including surgery and chemotherapy, could significantly decrease premature mortality in mTNBC patients.

As shown in Table 2, patients were randomly divided via a 7:3 ratio into 2 cohorts: a training cohort (n = 999) for nomogram building and a validation cohort (n = 429) for model validation. There were no significant differences between the training and validation cohorts in terms of age, sex, marital status, race, tumor laterality, histologic type, grading stage, TN stage (AJCC seventh edition), tumor size, surgery, radiotherapy, chemotherapy, tumor sequence number, brain metastases, liver metastases, and lung metastases. Therefore, the training and validation cohorts could be used for the follow-up study.

Factors Influencing Early Death in Patients With mTNBC

In this study, 275 eligible patients with mTNBC were included to investigate the factors associated with early mortality. The χ^2 and Fisher exact tests revealed that there were no significant differences between the training and validation cohorts for all variables. Subsequently, univariate and multivariate logistic regression analyses were conducted to identify influential factors. The results of the univariate logistic analysis revealed that age at diagnosis, marital status, tumor size, lymph node stage, brain metastasis, lung metastasis, liver metastasis, breast surgery, chemotherapy, and radiotherapy were potentially influential factors (Table 3). To further investigate the effect of metastatic pattern on survival, we included the number of metastatic organs in the logistic model, considering the interaction between metastatic site and number of metastatic organs. In the multivariate logistic analysis, age at diagnosis, tumor size, brain metastasis, liver metastasis, breast surgery, and chemotherapy were identified as independent prognostic factors for early mortality in patients with mTNBC (Table 3). The results indicated that older age at diagnosis ($P < 0.001$), larger primary tumor size ($P < 0.05$), the presence of brain metastasis ($P = 0.009$) and liver metastasis ($P < 0.001$), not receiving surgery ($P < 0.001$), and not receiving chemotherapy ($P < 0.001$) were independent factors associated with early death in patients with mTNBC.

Construction of Predictive Nomograms

Based on these 6 prognostic factors verified in Table 3, a predictive nomogram model was developed to assess the risk of early mortality in mTNBC (Fig. 2). This model can select the subcategories of each predictor variable based on individual characteristics and calculate the specific points by drawing a vertical line on the upper point axis. The total number of points is obtained by summing the points corresponding to all predictors.

TABLE 1. Baseline Clinical Characteristics of mTNBC Patients

Clinical characteristics	No (N = 1153), n (%)	Yes (N = 275), n (%)	Overall (N = 1428), n (%)
Age (y)			
< 49	299 (25.9)	32 (11.6)	331 (23.2)
50-59	321 (27.8)	50 (18.2)	371 (26.0)
60-69	286 (24.8)	74 (26.9)	360 (25.2)
70+	247 (21.4)	119 (43.3)	366 (25.6)
Race recode			
Black	265 (23.0)	65 (23.6)	330 (23.1)
Other	82 (7.1)	14 (5.1)	96 (6.7)
White	806 (69.9)	196 (71.3)	1002 (70.2)
Grade			
Grade I	11 (1.0)	2 (0.7)	13 (0.9)
Grade II	187 (16.2)	52 (18.9)	239 (16.7)
Grade III	934 (81.0)	215 (78.2)	1149 (80.5)
Grade IV	21 (1.8)	6 (2.2)	27 (1.9)
AJCC T 7th			
T1	146 (12.7)	41 (14.9)	187 (13.1)
T2	384 (33.3)	78 (28.4)	462 (32.4)
T3	237 (20.6)	51 (18.5)	288 (20.2)
T4	386 (33.5)	105 (38.2)	491 (34.4)
AJCC N 7th			
N0	242 (21.0)	86 (31.3)	328 (23.0)
N1	527 (45.7)	118 (42.9)	645 (45.2)
N2	134 (11.6)	26 (9.5)	160 (11.2)
N3	250 (21.7)	45 (16.4)	295 (20.7)
Histologic			
8500	946 (82.0)	215 (78.2)	1161 (81.3)
Other	207 (18.0)	60 (21.8)	267 (18.7)
Marital status			
Married	559 (48.5)	91 (33.1)	650 (45.5)
Never married	252 (21.9)	61 (22.2)	313 (21.9)
Other	342 (29.7)	123 (44.7)	465 (32.6)
Sequence number			
More primaries	253 (21.9)	58 (21.1)	311 (21.8)
One primary only	900 (78.1)	217 (78.9)	1117 (78.2)
Chemotherapy			
No	152 (13.2)	174 (63.3)	326 (22.8)
Yes	1001 (86.8)	101 (36.7)	1102 (77.2)
Radiotherapy			
No	715 (62.0)	212 (77.1)	927 (64.9)
Yes	438 (38.0)	63 (22.9)	501 (35.1)
Surgery			
No	509 (44.1)	211 (76.7)	720 (50.4)
Yes	644 (55.9)	64 (23.3)	708 (49.6)
Tumor size (mm)			
< 50	619 (53.7)	132 (48.0)	751 (52.6)
> 100	155 (13.4)	54 (19.6)	209 (14.6)
50-100	379 (32.9)	89 (32.4)	468 (32.8)
Bone metastasis			
No/unknown	697 (60.5)	144 (52.4)	841 (58.9)
Yes	456 (39.5)	131 (47.6)	587 (41.1)
Brain metastasis			
No/unknown	1052 (91.2)	221 (80.4)	1273 (89.1)
Yes	101 (8.8)	54 (19.6)	155 (10.9)
Lung metastasis			
No/unknown	717 (62.2)	142 (51.6)	859 (60.2)
Yes	436 (37.8)	133 (48.4)	569 (39.8)
Liver metastasis			
No/unknown	883 (76.6)	156 (56.7)	1039 (72.8)
Yes	270 (23.4)	119 (43.3)	389 (27.2)
Laterality			
Left	616 (53.4)	135 (49.1)	751 (52.6)
Right	537 (46.6)	140 (50.9)	677 (47.4)

Grade I: well differentiated; grade II: moderately differentiated; grade III: poorly differentiated; grade IV: undifferentiated. 8500: invasive ductal carcinoma (ICD-O-3, code 8500/3).

AJCC indicates American Joint Committee on Cancer.

Validation of the Nomogram

Figure 3A, B depicts the ROC curves of the nomograms for early death patients with mTNBC in the training and validation cohorts. The AUC value for the training cohort was 0.878 (95% CI: 0.850-0.9045), and the AUC value for the validation cohort was 0.857 (95% CI: 0.815-0.899), indicating the good predictive performance of the nomograms. In Figure 4, the *x*-axis of the calibration curve represents the predicted probability of early death, and the *y*-axis represents the actual probability of early death. Figure 4A, B shows that the GIVITI calibration curve does not cross the 95% CI area along the 45-degree line ($P > 0.05$), indicating the good fitting of the nomograms. The discrimination ability of the nomograms was evaluated using the DCA method. Figure 5A, B shows that the favorable threshold probability of the nomograms ranged from 0.0% to 83% in the training cohort analysis of early death, while the validation cohort analysis of early death ranged from 5.0% to 83%. The DCA results demonstrated that the nomograms have a wide range of threshold probabilities, displaying a promising potential to get superior net benefits.

Clinical Application

On the basis of this model, a dynamic web-based calculator was developed to facilitate the application of this nomogram. The calculator can predict the probability of early mortality in patients with mTNBC by inputting patient-specific clinical characteristics through the website (https://kevinpan.shinyapps.io/DynNom-Breast), along with its 95% CI. For example, for a patient with mTNBC aged 55 years with a primary tumor diameter of 60 mm and diagnosed with liver metastasis, the probability of early mortality after surgical treatment is 37.40% (Fig. 6A, B). However, if the patient receives chemotherapy in addition to surgery, the probability of early mortality is reduced to 5.11% (Fig. 6C, D). This example highlights the effectiveness of chemotherapy in reducing the risk of early mortality in mTNBC patients, which is helpful to quickly make effective clinical recommendations.

DISCUSSION

TNBC is a highly aggressive tumor that is prone to distant metastasis.[25] mTNBC is particularly malignant and often results in early death. In this study, we used a large sample with comprehensive clinical information from the SEER database to construct a predictive nomogram model and a web-based dynamic calculator for the probability predicting of early mortality in patients with mTNBC. The performance of this model was evaluated using ROC, calibration, and DCA curves. The results demonstrated the model's good performance in predicting early mortality in mTNBC patients. This model can provide guidance for clinical treatment and may assist clinicians in making treatment decisions and monitoring disease progression.

Although the prognosis for patients with mTNBC is poor, early detection is crucial for patients to receive appropriate treatment.[26] Therefore, identifying risk factors for mTNBC is important to guide clinical treatment. Several prognostic factors and biomarkers have been identified, including age, tumor size, linc-ZNF469-3, and miR-629-3p.[27–30] However, to our knowledge, there is no study to construct a nomogram model for predicting the risk of early death in mTNBC patients. Therefore, the risk of early death in this patient population cannot be quantified. Our results showed that age and tumor size were independent predictors of early death in patients with mTNBC, consistent with previous findings.

TABLE 2. Demographic Information of Patients With mTNBC in Training and Validation Cohorts

Clinical characteristics	Training (N = 999), n (%)	Validation (N = 429), n (%)	Overall (N = 1428), n (%)	χ^2	*P*
Age (y)	—	—	—	0.13571	0.9872
< 49	232 (23.2)	99 (23.1)	331 (23.2)	—	—
50-59	257 (25.7)	114 (26.6)	371 (26.0)	—	—
60-69	252 (25.2)	108 (25.2)	360 (25.2)	—	—
70+	258 (25.8)	108 (25.2)	366 (25.6)	—	—
Race recode	—	—	—	0.072292	0.9645
Black	232 (23.2)	98 (22.8)	330 (23.1)	—	—
Other	68 (6.8)	28 (6.5)	96 (6.7)	—	—
White	699 (70.0)	303 (70.6)	1002 (70.2)	—	—
Grade	—	—	—	0.0063	0.9999
Grade I	9 (0.9)	4 (0.9)	13 (0.9)	—	—
Grade II	167 (16.7)	72 (16.8)	239 (16.7)	—	—
Grade III	804 (80.5)	345 (80.4)	1149 (80.5)	—	—
Grade IV	19 (1.9)	8 (1.9)	27 (1.9)	—	—
AJCC T 7th	—	—	—	0.9999	0.8013
T1	134 (13.4)	53 (12.4)	187 (13.1)	—	—
T2	321 (32.1)	141 (32.9)	462 (32.4)	—	—
T3	196 (19.6)	92 (21.4)	288 (20.2)	—	—
T4	348 (34.8)	143 (33.3)	491 (34.4)	—	—
AJCC N 7th	—	—	—	0.7998	0.8495
N0	227 (22.7)	101 (23.5)	328 (23.0)	—	—
N1	457 (45.7)	188 (43.8)	645 (45.2)	—	—
N2	108 (10.8)	52 (12.1)	160 (11.2)	—	—
N3	207 (20.7)	88 (20.5)	295 (20.7)	—	—
Histologic	—	—	—	0.6128	0.4337
8500	818 (81.9)	343 (80.0)	1161 (81.3)	—	—
Others	181 (18.1)	86 (20.0)	267 (18.7)	—	—
Marital status	—	—	—	2.0127	0.3656
Married	465 (46.5)	185 (43.1)	650 (45.5)	—	—
Never married	210 (21.0)	103 (24.0)	313 (21.9)	—	—
Others	324 (32.4)	141 (32.9)	465 (32.6)	—	—
Sequence number	—	—	—	0.5026	0.4783
More primaries	212 (21.2)	99 (23.1)	311 (21.8)	—	—
One primary only	787 (78.8)	330 (76.9)	1117 (78.2)	—	—
Chemotherapy	—	—	—	0.1242	0.7245
No	225 (22.5)	101 (23.5)	326 (22.8)	—	—
Yes	774 (77.5)	328 (76.5)	1102 (77.2)	—	—
Radiotherapy	—	—	—	2.4765	0.1156
No	635 (63.6)	292 (68.1)	927 (64.9)	—	—
Yes	364 (36.4)	137 (31.9)	501 (35.1)	—	—
Surgery	—	—	—	0.2348	0.6280
No	499 (50.0)	221 (51.5)	720 (50.4)	—	—
Yes	500 (50.1)	208 (48.5)	708 (49.6)	—	—
Tumor size (mm)	—	—	—	3.7536	0.1531
< 50	524 (52.5)	227 (52.9)	751 (52.6)	—	—
> 100	136 (13.6)	73 (17.0)	209 (14.6)	—	—
50-100	339 (33.9)	129 (30.1)	468 (32.8)	—	—
Bone metastasis	—	—	—	12.514	0.0004
No/unknown	619 (62.0)	222 (51.7)	841 (58.9)	—	—
Yes	380 (38.0)	207 (48.3)	587 (41.1)	—	—
Brain metastasis	—	—	—	0.2966	0.5860
No/unknown	894 (89.5)	379 (88.3)	1273 (89.1)	—	—
Yes	105 (10.5)	50 (11.7)	155 (10.9)	—	—
Lung metastasis	—	—	—	0.1644	0.6851
No/unknown	597 (59.8)	262 (61.1)	859 (60.2)	—	—
Yes	402 (40.2)	167 (38.9)	569 (39.8)	—	—
Liver metastasis	—	—	—	0.7404	0.3895
No/unknown	734 (73.5)	305 (71.1)	1039 (72.8)	—	—
Yes	265 (26.5)	124 (28.9)	389 (27.2)	—	—
Survival status	—	—	—	3.5574	0.0592
No	820 (82.1)	333 (77.6)	1153 (80.7)	—	—
Yes	179 (17.9)	96 (22.4)	275 (19.3)	—	—
Laterality	—	—	—	0.4627	0.4963
Left	519 (52.0)	232 (54.1)	751 (52.6)	—	—
Right	480 (48.0)	197 (45.9)	677 (47.4)	—	—

Grade I: well differentiated; grade II: moderately differentiated; grade III: poorly differentiated; grade IV: undifferentiated. 8500: invasive ductal carcinoma (ICD-O-3, code 8500/3). AJCC indicates American Joint Committee on Cancer.

TABLE 3. The Univariate and Multivariate Logistic Analysis of Risk Factors for Early Death From mTNBC

	Univariable			Multivariable		
Clinical characteristics	**OR**	**95% CI**	***P***	**OR**	**95% CI**	***P***
Age (y)						
< 49						
50-59	1.988	1.189-3.415	0.0313*	1.790	0.979-3.354	0.1183*
60-69	3.095	1.900-5.213	0.0002*	2.544	1.416-4.711	0.0103*
70+	6.402	4.037-10.571	< 0.0001*	4.373	2.414-8.181	< 0.0001*
Race recode						
Black	—	—	—	—	—	—
Others	0.616	0.310-1.145	0.2200	—	—	—
White	0.871	0.638-1.202	0.4760	—	—	—
Grade						
Grade I	—	—	—	—	—	—
Grade II	2.198	0.492-22.296	0.4646	—	—	—
Grade III	1.643	0.378-16.466	0.6409	—	—	—
Grade IV	2.857	0.501-32.034	0.3743	—	—	—
AJCC T 7th						
T1	—	—	—	—	—	—
T2	0.766	0.493-1.207	0.3270	—	—	—
T3	1.014	0.634-1.636	0.9600	—	—	—
T4	1.078	0.709-1.668	0.7710	—	—	—
AJCC N 7th						
N0	—	—	—	—	—	—
N1	0.609	0.439-0.846	0.0126*	—	—	—
N2	0.531	0.312-0.873	0.0422*	—	—	—
N3	0.537	0.355-0.805	0.0125*	—	—	—
Histologic						
8500	—	—	—	—	—	—
Others	1.223	0.865-1.706	0.3280	—	—	—
Marital status						
Married	—	—	—	—	—	—
Never married	1.253	0.855-1.818	0.3243	—	—	—
Others	2.054	1.513-2.795	0.0001*	—	—	—
Sequence number						
More primaries	—	—	—	—	—	—
One primary only	1.085	0.780-1.533	0.6890	—	—	—
Chemotherapy						
No	—	—	—	—	—	—
Yes	0.083	0.060-0.112	< 0.0001*	0.093	0.063-0.134	< 0.0001*
Radiotherapy						
No	—	—	—	—	—	—
Yes	0.457	0.331-0.622	< 0.0001*	—	—	—
Surgery						
No	—	—	—	—	—	—
Yes	0.225	0.162-0.307	< 0.0001*	0.201	0.133-0.297	< 0.0001*
Tumor size (mm)						
< 50	—	—	—	—	—	—
> 100	1.658	1.118-2.429	0.0315*	2.279	1.395-3.709	0.0054*
50-100	1.278	0.944-1.726	0.1791	1.594	1.080-2.357	0.0487*
Bone metastasis						
No/unknown	—	—	—	—	—	—
Yes	1.183	0.896-1.559	0.3150	—	—	—
Brain metastasis						
No/unknown	—	—	—	—	—	—
Yes	2.111	1.430-3.074	0.0013*	2.264	1.343-3.809	0.0097*
Lung metastasis						
No/unknown	—	—	—	—	—	—
Yes	1.646	1.253-2.163	0.0027*	—	—	—
Liver metastasis						
No/unknown	—	—	—	—	—	—
Yes	2.391	1.798-3.174	< 0.0001*	3.137	2.174-4.55	< 0.0001*
Laterality						
Left	—	—	—	—	—	—
Right	1.055	0.804-1.385	0.7420	—	—	—

Grade I: well differentiated; grade II: moderately differentiated; grade III: poorly differentiated; grade IV: undifferentiated. 8500: invasive ductal carcinoma (ICD-O-3, code 8500/3).

*$P < 0.05$.

AJCC indicates American Joint Committee on Cancer; OR, odds ratio.



FIGURE 2. A predictive prognostic nomogram for predicting early death in patients with metastatic triple-negative breast cancer. full color online

In addition, our findings showed that patients without brain and liver metastases had a better prognosis after undergoing surgery and chemotherapy. We constructed an early death prognostic nomogram based on 6 independent prognostic factors, which can be useful in identifying high-risk patients. We found that patients with distant metastases had a lower survival rate, which is consistent with the findings of Wang et al.[31] Moreover, different sites of metastasis also affect the survival of mTNBC patients. The prognosis of mTNBC patients with brain and liver metastases was much worse than that with lung and bone metastases. Some studies have also reported that patients with visceral metastases have a worse prognosis than those with bone metastases.[32] Typically, treating patients with advanced diseases should focus on improving



FIGURE 3. Receiver operating characteristic (ROC) curves for the nomogram. A, The ROC curve for the training cohort early death nomogram in the Surveillance, Epidemiology, and End Results database. B, ROC curve for the validation cohort early death nomogram in the SEER database. AUC indicates area under the time-dependent receiver operating characteristic curve. full color online



FIGURE 4. GIVITI Calibration belt plots for the nomogram of training cohort early death in the Surveillance, Epidemiology, and End Results database (A); validation cohort early death in the Surveillance, Epidemiology, and End Results database (B). full color online

survival. Previous studies have also shown that chemotherapy and surgery significantly improve the prognosis of patients with mTNBC.[33] This is consistent with our findings that surgery and chemotherapy favor the survival of patients with mTNBC, as demonstrated by our prognostic nomogram.

At present, chemotherapy is still the standard treatment for patients with mTNBC.[34] The change in the chemotherapy scheme not only improves the prognosis but also provides more treatment options. The National Comprehensive Cancer Network guidelines recommend a combination regimen based on paclitaxel, anthracyclines, cyclophosphamide, cisplatin, and fluorouracil for treating mTNBC.[7] A phase III randomized clinical trial investigated the efficacy and safety of cisplatin in combination with nab-paclitaxel or gemcitabine as first-line treatment for mTNBC, showing that patients receiving nab-paclitaxel had a more prolonged progression-free survival than those treated with the gemcitabine regimen (9.8 vs. 7.4 months).[35] Furthermore, previous studies have demonstrated that patients can benefit from surgery despite metastasis to distant organs.[36,37] Recently, immunotherapy and targeted therapies have emerged as new treatment modalities for mTNBC, potentially improving patient life expectancy and quality of life. The KEYNOTE-355 trial investigated the efficacy and safety of adding immunotherapy (pembrolizumab) to chemotherapy scheme in 847 cases of advanced TNBC. In patients with overexpressed programmed death ligands, the survival treated with the combination of pembrolizumab was significantly higher than that treated with chemotherapy alone. In addition, previous studies have shown that novel targeted therapies may be promising for patients with TNBC. Therefore, the risk factors identifying early death may help to identify high-risk patients and establish a specific monitoring program.

Our study has several limitations. First, the information collected in the SEER database pertains to the disease at the initial diagnosis, which means that cases of mTNBC occurring later cannot be included. Second, the SEER database does not currently collect information on other metastatic sites, such as distant lymph nodes, pleura, peritoneum, or skin. Third, this is a retrospective study with a large sample size, which may result in selection bias. Furthermore, we could not consider the influence of other clinical factors and biomarkers, such as targeted therapies, postoperative complications, gene expression, and chromosomal alterations, which excluded in the database. Finally, the SEER database does not provide detailed



FIGURE 5. Decision curve analysis curves for the nomogram of training cohort early death (A) and validation cohort early death in the Surveillance, Epidemiology, and End Results database (B). full color online



FIGURE 6. Probability of early postoperative death in a 55-year-old metastatic triple-negative breast cancer patient with a primary tumor of 60 mm with liver metastases (A, B). Probability of early death after postoperative chemotherapy treatment in a 55-year-old metastatic triple-negative breast cancer patient with a primary tumor of 60 mm with liver metastases (C, D). CHO indicates presence or absence of chemotherapy; SEER, Surveillance, Epidemiology, and End Results; SUR, whether primary site surgery was performed. full color online

information on chemotherapy and radiotherapy regimens, which may have a differential impact on survival or life quality in patients with mTNBC.

CONCLUSIONS

Age, tumor size, liver metastases, brain metastases, surgery, and chemotherapy were identified as independent prognostic factors affecting early mortality in patients with mTNBC in this study. These results will assist researchers and clinicians in developing individualized treatment plans and ensuring appropriate disease management for patients with mTNBC. A web-based survival prediction model utilizing these prognostic factors to predict the risk of early death in mTNBC could help clinicians establish more effective clinical management and treatment strategies. Patients at high risk of early mortality, as predicted by the model, may benefit more from intensive treatment and care, which could potentially improve their outcomes. Prospective clinical studies are still required to validate the utility and clinical value of this prediction model for patients with mTNBC.

ACKNOWLEDGMENTS

The authors thank the anonymous peer-reviewers for the careful reading of the manuscript and many insightful comments and suggestions.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68:394–424.
2. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. *J Clin Oncol*. 2013;31:3997–4013.
3. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. *Cancer Control*. 2010;17:173–176.
4. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. *Eur J Cancer*. 2009;45:27–40.
5. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*. 2007;13:4429–4434.
6. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med*. 2010;363:1938–1948.
7. Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res*. 2020;22:61.
8. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. *Cancer*. 2008;113:2638–2645.
9. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer—current status and future directions. *Ann Oncol*. 2009;20:1913–1927.
10. Zhang J, Lin Y, Sun XJ, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. *Ann Oncol*. 2018;29:1741–1747.
11. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet*. 2020;396:1817–1828.

12. Kang C, Syed YY. Atezolizumab (in combination with nab-paclitaxel): a review in advanced triple-negative breast cancer. *Drugs*. 2020;80:601–607.
13. Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*. 2017;18:1360–1372.
14. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018;379:2108–2121.
15. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2020;21:44–59.
16. Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. *Lancet Oncol*. 2015;16:e173–e180.
17. Song C, Yu D, Wang Y, et al. Dual primary cancer patients with lung cancer as a second primary malignancy: a population-based study. *Front Oncol*. 2020;10:515606.
18. Shen H, Deng G, Chen Q, et al. The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database. *BMC Cancer*. 2021;21:825.
19. Song Z, Zhou Y, Bai X, et al. A practical nomogram to predict early death in advanced epithelial ovarian cancer. *Front Oncol*. 2021;11:655826.
20. Huang Z, Hu C, Liu K, et al. Risk factors, prognostic factors, and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast: a population-based study. *BMC Cancer*. 2020;20:1145.
21. Janssens ACJW, Martens FK. Reflection on modern methods: revisiting the area under the ROC Curve. *Int J Epidemiol*. 2020;49:1397–1403.
22. Van Oirbeek R, Lesaffre E. An application of Harrell's C-index to PH frailty models. *Stat Med*. 2010;29:3160–3171.
23. Finazzi S, Poole D, Luciani D, et al. Calibration belt for quality-of-care assessment based on dichotomous outcomes. Gravenor M, editor. *PLoS One*. 2011;6:e16110.
24. Van Calster B, Wynants L, Verbeek JFM, et al. Reporting and interpreting decision curve analysis: a guide for investigators. *Eur Urol*. 2018;74:796–804.
25. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. *Ann Oncol*. 2012;23:vi7–vi12.
26. Tseng LM, Hsu NC, Chen SC, et al. Distant metastasis in triple-negative breast cancer. *Neoplasma*. 2013;60:290–294.
27. Wang PS, Chou CH, Lin CH, et al. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. *Oncogene*. 2018;37:4662–4678.
28. Wang J, Song C, Tang H, et al. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. *Breast Cancer Res*. 2017;19:72.
29. Xiao W, Zheng S, Yang A, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. *Cancer Manag Res*. 2018;10:5329–5338.
30. Yao Y, Chu Y, Xu B, et al. Risk factors for distant metastasis of patients with primary triple-negative breast cancer. *Biosci Rep*. 2019;39:BSR20190288.
31. Wang Z, Wang H, Sun X, et al. A risk stratification model for predicting overall survival and surgical benefit in triple-negative breast cancer patients with de novo distant metastasis. *Front Oncol*. 2020;10:14.
32. Ahn SG, Lee HM, Cho SH, et al. Prognostic factors for patients with bone-only metastasis in breast cancer. *Yonsei Med J*. 2013;54:1168.
33. Gu Y, Wu G, Zou X, et al. Prognostic value of site-specific metastases and surgery in de novo stage IV triple-negative breast cancer: a population-based analysis. *Med Sci Monit*. 2020;26:e920432.
34. Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nat Rev Clin Oncol*. 2016;13:674–690.
35. Wang B, Sun T, Zhao Y, et al. A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. *Nat Commun*. 2022;13:4025.
36. Chen MT, Sun HF, Zhao Y, et al. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. *Sci Rep*. 2017;7:9254.
37. Wang K, Shi Y, Li ZY, et al. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: a real-world observational study. *Eur J Surg Oncol*. 2019;45:1364–1372.